NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
Clinical Trials
14 trialsNCT00526396 2023-03-24
STAD-1
National Cancer Institute, Naples
Phase 3 Unknown
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT02337712 2021-01-27
Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04363255 2020-04-28
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Taizhou Hospital
Phase 2 Unknown
NCT03585998 2020-03-02
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
Samsung Medical Center
Phase 2 Unknown
NCT03613597 2020-02-05
Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer
Guizhou Medical University
Phase 2 Unknown
NCT03781869 2018-12-20
Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
Third Military Medical University
Phase 2 Unknown
NCT02348450 2016-12-05
Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
Guangdong Association of Clinical Trials
Phase 4 Unknown
NCT02875457 2016-08-24
Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin
Third Military Medical University
Phase 3 Unknown
NCT01977235 2016-04-01
TDICC
Third Military Medical University
Phase 2 Unknown
NCT00178698 2011-03-03
FR-WB-TT/che
The University of Texas Health Science Center, Houston
Phase 2 Unknown
NCT00546130 2008-09-03
RNCLC
University of Toyama
Phase 2 Unknown